Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies

Abstract:
PDS Biotechnology Corporation today announced that the company has been selected as a collaborator of the US National Cancer Institute's Nanotechnology Characterization Lab (NCL) to complete preclinical development of Versamune(TM)-HPV prior to filing of the Investigational New Drug Application. The NCL will perform selected physical, chemical and biological studies on behalf of the company at its facilities at the National Cancer Institute (NCI) in Frederick, Maryland. Dr. Frank Bedu-Addo, President of the Corporation stated that, "PDS Biotechnology Corporation's partnership with the NCL provides significant value to the company. The invaluable expertise of the NCL's scientists will provide the company with additional expert resources and technologies, and will facilitate rapid development of the product."

PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies

CINCINNATI, OH | Posted on November 6th, 2008

Versamune(TM)-HPV is an immunotherapy drug which has demonstrated significant promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Cancers caused by infection with the human papilloma virus (HPV) include cervical, head and neck and anal cancers. No cures exist for these cancers. Based on promising in vivo and in vitro efficacy data, PDS Biotechnology Corporation was awarded in August 2008, a phase I SBIR grant by the US National Institutes of Health/National Cancer Institute to develop Versamune(TM)-Melanoma to treat melanoma, which is the most aggressive form of skin cancer.

PDS Biotechnology Corporation's Versamune(TM) nanotechnology facilitates the uptake of disease-associated protein and peptide antigens by the antigen- presenting cells of the immune system and simultaneously acts a strong immune system activator (adjuvant) without the inflammatory side effects induced by current adjuvants. The result is simple, safe and cost effective nanotechnology-based drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular protein formulated with Versamune(TM).

####

About PDS Biotechnology Corporation
PDS Biotechnology Corporation (www.pdsbiotech.com) is a Cincinnati, Ohio-based biotechnology company applying the company's proprietary Versamune(TM) nanotechnology drug platform technology to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.

The NCL is a formal collaboration between the US National Cancer Institute, the US Food and Drug Administration (FDA) and the National Institute of Standards and Technologies (NIST) to rapidly advance promising cancer nanotechnology drugs through regulatory submissions with the FDA.

For more information, please click here

Contacts:
PDS Biotechnology Corporation
3130 Highland Avenue
Third Floor
Cincinnati, Ohio 45219
Tel: 513-475-6610
Fax: 513-221-1891

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Building a smart cardiac patch: 'Bionic' cardiac patch could one day monitor and respond to cardiac problems June 28th, 2016

New, better way to build circuits for world's first useful quantum computers June 28th, 2016

Yale researchersí technology turns wasted heat into power June 27th, 2016

FEI Launches Helios G4 DualBeam Series for Materials Science: The Helios G4 DualBeam Series features new capabilities to enable scientists and engineers to answer the most demanding and challenging scientific questions June 27th, 2016

Laboratories

Titan shines light on high-temperature superconductor pathway: Simulation demonstrates how superconductivity arises in cuprates' pseudogap phase June 22nd, 2016

Discovery of gold nanocluster 'double' hints at other shape-changing particles: New analysis approach brings two unique atomic structures into focus June 19th, 2016

Efficient hydrogen production made easy: Sticking electrons to a semiconductor with hydrazine creates an electrocatalyst June 17th, 2016

Discovery of gold nanocluster 'double' hints at other shape changing particles: New analysis approach brings two unique atomic structures into focus June 15th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Nanoscientists develop the 'ultimate discovery tool': Rapid discovery power is similar to what gene chips offer biology June 25th, 2016

Ultrathin, flat lens resolves chirality and color: Multifunctional lens could replace bulky, expensive machines June 25th, 2016

Particle zoo in a quantum computer: First experimental quantum simulation of particle physics phenomena June 23rd, 2016

Titan shines light on high-temperature superconductor pathway: Simulation demonstrates how superconductivity arises in cuprates' pseudogap phase June 22nd, 2016

Nanomedicine

Building a smart cardiac patch: 'Bionic' cardiac patch could one day monitor and respond to cardiac problems June 28th, 2016

Nanoscientists develop the 'ultimate discovery tool': Rapid discovery power is similar to what gene chips offer biology June 25th, 2016

Nanotechnology and math deliver two-in-one punch for cancer therapy resistance June 24th, 2016

Self-assembling icosahedral protein designed: Self-assembling icosahedral protein designed June 22nd, 2016

Appointments/Promotions/New hires/Resignations/Deaths

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

Park Systems Global Expansion in AFM Market Includes Appointment of New Executives April 23rd, 2016

GLOBALFOUNDRIES Adds Alain Mutricy as Head of Product Management Group March 3rd, 2016

George Clark Named Chief Financial Officer and Associate Laboratory Director for Business Services at Brookhaven Lab February 24th, 2016

Alliances/Trade associations/Partnerships/Distributorships

FEI and University of Liverpool Announce QEMSCAN Research Initiative: University of Liverpool will utilize FEIís QEMSCAN technology to gain a better insight into oil and gas reserves & potentially change the approach to evaluating them June 22nd, 2016

French Research Team Helps Extend MRI Detection of Diseases & Lower Health-Care Costs: CEA, INSERM and G2ELab Brings Grenoble Regionís Expertise In Advanced Medicine & Magnetism Applications to H2020 IDentIFY Project June 21st, 2016

Research showing why hierarchy exists will aid the development of artificial intelligence June 13th, 2016

UK NANOSAFETY GROUP publishes 2nd Edition of guidance to support safe working with nanomaterials May 30th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic